Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
December 1, 2022
Ryan Allway December 1st, 2022 Psychedelics, Top News ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. ( Nasdaq: SILO ) (“the Company”) , a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company’s progress and potential for its portfolio of... Read more
Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind’s Proprietary MEAI Compound
November 18, 2021
Ryan Allway November 18th, 2021 Psychedelics Professor Gal Yadid, renowned neuropsychopharmacologist, to spearhead the project Toronto, Ontario–(Newsfile Corp. – November 18, 2021) – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived... Read more
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
September 10, 2021
Ryan Allway September 10th, 2021 Psychedelics The investment provides CaaMTech with capital to advance compounds from its library into clinical trials ISSAQUAH, Wash., Sept. 08, 2021 (GLOBE NEWSWIRE) — CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round,... Read more
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio
July 14, 2021
Ryan Allway July 14th, 2021 Psychedelics Industry Veteran Dr. Adi Zuloff-Shani Takes The Helm As CEO Toronto, Ontario–(Newsfile Corp. – July 14, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve... Read more
Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies
June 16, 2021
Ryan Allway June 16th, 2021 Psychedelics TORONTO, June 16, 2021 /CNW/ – Wake Network Inc. (“Wake” or the “Company“), a global leader in psilocybin and medicinal mushroom production and developer of genomics-based integration therapies, is pleased to announce that it has entered into an agreement with Santé Cannabis (“Sante”) for consultation and... Read more
BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors
Biotechnology June 2, 2021
Ryan Allway June 2nd, 2021 Psychedelics VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has appointed Mr. Henri Sant-Cassia, co-founder of The... Read more
Ryan Allway May 18th, 2021 Psychedelics Invests in care support systems to facilitate rapid expansion TORONTO, ON / ACCESSWIRE / May 18, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, has opened a new Novamind Client Care Center (“Client... Read more
Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board
April 13, 2021
Ryan Allway April 13th, 2021 Psychedelics Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect. Bringing nearly two decades of experience in the pharmaceuticals industry, Adam served as Chief Financial... Read more
